Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ATR 1072

Oligonucleotide (siRNA) · Gene silencing: PRKAG2 · developed by Atrium Therapeutics

Phase 1/2 Most advanced trial
RNA Developer
1 Registered trials

What is ATR 1072?

ATR 1072 is an investigational siRNA therapy delivered by intravenous infusion that reduces expression of the PRKAG2 gene. It is being studied in cardiac glycogenosis, hypertrophic cardiomyopathy and Wolff-Parkinson-White syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
PRKAG2
Mechanism
Gene silencing: PRKAG2
Therapy area
Cardiovascular, Metabolic
Developer
Atrium Therapeutics (RNA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07738107 Phase 1/2 Cardiac Glycogenosis Recruiting RNA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Cardiac GlycogenosisCardiomyopathyHypertrophicWolff-Parkinson-White Syndrome

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RNA page.

Follow RNA, the company behind ATR 1072

See RNA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RNA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.